CTSC:TTIC.062210

From NAMIC Wiki
Jump to: navigation, search
Home < CTSC:TTIC.062210

Back to Collaboration:Harvard_CTSC

Agenda

  1. Consultations
  2. Education program
  3. Plan for ACRIN
  4. Multicenter trial

Harvard Translational Imaging Consortium Meeting Minutes June 22, 2010

In attendance:

  • Valerie Humblet
  • Simon Warfield
  • Gordon Williams
  • Annick Van den Abbeele
  • Bob Lenkinski
  • Bruce Rosen


1. Consultations

  • JIRA # 159: Valerie will re contact the PI now that she found a couple of people with FSL routines expertise that could be potential consultants.
  • Valerie will compile the hours spent on the consultations from 11/09 to 04/10.


2. Education program

  • Bob talked to Warren Manning who expressed his interest in giving lectures during our coming cardiovascular sessions.
  • Simon is working on the segmentation and validation presentation.
  • Valerie will contact Greg Sorensen to check his availability to give a lecture during the neuroimaging sessions.


3. Plan for ACRIN meeting

  • The CTSA imaging working group is planning to have a one day working session at the ACRIN meeting (Pentagon City, Sept28-Oct2). Randy mentioned the mi2b2 project during the last t-con of the CTSA IWG and other groups were very interested and would like to learn more. We will plan to give a 20-30 minutes talk about the project. First we will send Dan Sullivan an overview of mi2b2 before the next CTSA IWG steering committee (July 15).


4. Multicenter trial

  • The group had its 2nd meeting. Both Charles (MRI) and Jeff (PET/CT) provided material on how to qualify sites, do the quality insurance etc.
  • The aims of the group are:
    • to prepare a set of guidelines on how to enroll patients, qualify sites with phantoms. Anyone who has a prospective idea for a multicenter trial will be able to access these documents.
    • to catalogue existing multicenter trials
  • Bruce Rosen suggested to contact Karl Helmer (Martinos Center) who has a tremendous expertise in design and optimization of multi-site magnetic resonance imaging trials.